Deals Of The Week Discusses Pharma’s Need For Disruptive Collaboration
Two CEOs describe their approach to virtual partnerships, corporate renewal, and active risk management. Plus, more conventional divestment and M&A deals from Novartis and Grifols and Roche and immatics.
You may also be interested in...
Shire’s ViroPharma Purchase Aims To Build Rare Disease Giant
Shire is buying ViroPharma at a steep premium to acquire its pipeline assets, notably C1 esterase inhibitor Cinryze, which the London-listed specialty pharma plans to expand internationally, initially to treat hereditary angioedema and later for other rare diseases.
Saving Face? Cell Therapeutics Withdraws Pixantrone NDA Ahead Of Advisory Committee Review
Company’s announcement that it pulled the NDA for its investigational non-Hodgkin’s lymphoma treatment comes after the sponsor would have received FDA’s background briefing document for the Feb. 9 Oncologic Drugs Advisory Committee meeting.
Deals Of The Week: Forma/Boehringer Ingelheim, Biogen/Isis, Alnylam/Arrowhead
Industry business-development executives rang in the New Year with a half-dozen deals, including Forma’s second big partnership in six months and a joint licensing agreement between Alnylam and Arrowhead.